Our therapeutic candidate, TPX-100, has demonstrated to improve knee function and reduce pathological structural changes of the knee joint in knee osteoarthritis patients in its previous clinical trial in the U.S.  It is now in a Phase 2b clinical trial...

Our therapeutic candidate, TPX-100, has demonstrated to improve knee function and reduce pathological structural changes of the knee joint in knee osteoarthritis patients in its previous clinical trial in the U.S. It is now in a Phase 2b clinical trial. The company is aiming to develop this product as a first-in-class disease modifying osteoarthritis drug. (PRNewsFoto/OrthoTrophix, Inc.)

Two studies at ACR Convergence 2026 suggest potential structural effects of TPX-100 and identify patients who may benefit most.

FOSTER CITY, Calif., Nov. 9, 2026 /PRNewswire/ -- OrthoTrophix, Inc., a privately held biopharmaceutical company, today announced data from two posters at ACR Convergence 2026 in Orlando, Florida (November 6–11) showing a significant association between MRI-based femoral bone shape, measured by B-score, and meniscal pathology in knee osteoarthritis (KOA).

Originally published on the BLOX Digital Content Exchange.